Document is current

Article History

Received: 7 March 2022

Accepted: 4 October 2022

First Online: 21 November 2022

Competing interests

: J.S. and I.L.W. licensed a patent to Forty Seven/Gilead on the use of CD47-blocking strategies in SCLC. J.S. has equity in and is an advisor for, DISCO Pharmaceuticals. I.L.W. is a director, stockholder and consultant in Forty Seven, a public company that was involved in CD47-based immunotherapy of cancer but was acquired by Gilead. At the time of this submission, I.L.W. has no formal relationship with Gilead. I.L.W. is a co-founder, Director and consultant for Bitterroot Bio, a company working on atherosclerosis from the anti-CD47 angle. I.L.W. is also a co-founder, Director and consultant for PHeast, a company testing new ‘don’t eat me’ signals with more limited cancer type distributions, including CD24. I.L.W. is co-founding 48, a company establishing antibody cocktails to prepare blood-forming stem cell recipients, both autologous and allogeneic, for hematopoietic stem cell engraftment without any radiation or chemotherapy. None of these companies fund the Weissman laboratory. I.L.W. is also on the scientific advisory board of Appia, a CAR-iNK company for cancer therapies. Y.N., E.E.G. and J.S. filed a patent based on these data (PCT/US2021/046548). A.T. reports research funding to the institution from the following entities: EMD Serono Research & Development Institute; AstraZeneca; Tarveda Therapeutics; Immunomedics and Prolynx. The authors declare no other competing interests.